ID   NPC-B13
AC   CVCL_D3FG
DR   Wikidata; Q127382966
RX   Patent=US20220373534;
RX   PubMed=34204797;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-127019.
CC   Population: Chinese; Taiwan.
CC   Characteristics: Established from a patient-derived xenograft established in NOD/SCID mice (PubMed=34204797).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
ST   Source(s): Patent=US20220373534
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D10S1248: 13,15
ST   D12S391: 19,23
ST   D13S317: 8
ST   D16S539: 9
ST   D18S51: 15
ST   D19S433: 14,14.2
ST   D1S1656: 11,16,17
ST   D21S11: 29,30
ST   D22S1045: 16
ST   D2S1338: 18,23
ST   D2S441: 12,14
ST   D3S1358: 16
ST   D5S818: 11
ST   D7S820: 11
ST   D8S1179: 12
ST   FGA: 27
ST   Penta D: 8,12
ST   Penta E: 15
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 14,16
DI   NCIt; C3871; Nasopharyngeal carcinoma
DI   ORDO; Orphanet_150; Nasopharyngeal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   52Y
CA   Cancer cell line
DT   Created: 30-01-24; Last updated: 10-04-25; Version: 3
//
RX   Patent=US20220373534;
RA   Hsu C.-L.;
RT   "Human nasopharyngeal carcinoma cells derived from patient derived
RT   xenograft and uses thereof.";
RL   Patent number US20220373534, 24-Nov-2022.
//
RX   PubMed=34204797; DOI=10.3390/cancers13122954; PMCID=PMC8231497;
RA   Li H.-P., Huang C.-Y., Lui K.-W., Chao Y.-K., Yeh C.-N., Lee L.-Y.,
RA   Huang Y.-L., Lin T.-L., Kuo Y.-C., Huang M.-Y., Lai Y.-R., Yeh Y.-M.,
RA   Fan H.-C., Lin A.-C., Hsieh J.C.-H., Chang K.-P., Lin C.-Y., Wang H.-M.,
RA   Chang Y.-S., Hsu C.-L.;
RT   "Combination of epithelial growth factor receptor blockers and CDK4/6
RT   inhibitor for nasopharyngeal carcinoma treatment.";
RL   Cancers (Basel) 13:2954.1-2954.18(2021).
//